The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-28. Anything still debated is marked as such rather than presented as settled.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
=== Boer organization and skills === War was declared on 11 October with a Boer offensive into the British-held Natal and Cape Colony areas. The Boers had about 33,000 soldiers, and outnumbered the British, who could move only 13,000 troops to the front line. The Boers had no problems with mobilisation, since the independent Boers had no regular army units, apart from the Staatsartillerie (Dutch for 'State Artillery'). As with the First Boer War, since most of the Boers were members of civilian militias, none had adopted uniforms or insignia. Only the members of the Staatsartillerie wore light green uniforms.
=== We–Wh === Edwin C. Webb (1921–2006). British (later Australian) biochemist at the University of Queensland and Macquarie University. Editor of Enzyme Nomenclature until 1992. Gregorio Weber (1916–1997). Argentinian spectroscopist at the University of Illinois, who pioneered the application of fluorescence spectroscopy to the biological sciences. Member Natl. Acad. Sci. USA, National Academy of Sciences of Argentina. Stephen C. West FRS (b. 1952). British biochemist at the Francis Crick Institute, London, known for his work on DNA recombination and repair. Foreign Associate Natl. Acad. Sci. USA. Hans Westerhoff (b. 1953). Dutch biochemist at the Universities of Amsterdam and of Manchester, known for work in systems biology and metabolic regulation. Frank Henry Westheimer (1912–2007). American chemist at Harvard who did pioneering work in physical organic chemistry, applying techniques from physical to organic chemistry and integrating the two fields. Member Natl. Acad. Sci. USA. John Westley (b. 1927). American enzymologist at the University of Chicago known for work on rhodanese and sulfurtransferases in general. Frederick Whatley (1924–2020). British botanist and biochemist at the University of Sydney known for work on photosynthesis. William Joseph Whelan FRS (1924–2021). British-American biochemist at the University of Miami, who worked on the structure of glycogen, and discovered the protein glycogenin at its core. He was very active in the creation of international organizations, including the IUB (now IUBMB) and FEBS.
Paleodemography studies demographic characteristics of past populations. Bioarchaeologists use paleodemography to create life tables, a type of cohort analysis, to understand demographic characteristics (such as risk of death or sex ratio) of a given age cohort within a population. It is often necessary to estimate the age and sex of individuals based on specific morphological characteristics of the skeleton.
Sources: en.wikipedia.org
Neptunium nitride (NpN) was first prepared in 1953 by reacting neptunium hydride and ammonia gas at around 750 °C in a quartz capillary tube. Later, it was produced by reacting different mixtures of nitrogen and hydrogen with neptunium metal at various temperatures. It has also been produced by the reduction of neptunium dioxide with diatomic nitrogen gas at 1550 °C. NpN is isomorphous with uranium mononitride (UN) and plutonium mononitride (PuN) and has a melting point of 2830 °C under a nitrogen pressure of around 1 MPa. Two neptunium phosphide compounds have been reported, NpP and Np3P4. The first has a face centered cubic structure and is prepared by converting neptunium metal to a powder and then reacting it with phosphine gas at 350 °C. Np3P4 can be produced by reacting neptunium metal with red phosphorus at 740 °C in a vacuum and then allowing any extra phosphorus to sublimate away. The compound is non-reactive with water but will react with nitric acid to produce Np(IV) solution. Three neptunium arsenide compounds have been prepared, NpAs, NpAs2, and Np3As4. The first two were first produced by heating arsenic and neptunium hydride in a vacuum-sealed tube for about a week. Later, NpAs was also made by confining neptunium metal and arsenic in a vacuum tube, separating them with a quartz membrane, and heating them to just below neptunium's melting point of 639 °C, which is slightly higher than the arsenic's sublimation point of 615 °C. Np3As4 is prepared by a similar procedure using iodine as a transporting agent. NpAs2 crystals are brownish gold and Np3As4 is black.
{\displaystyle {\begin{aligned}{\boldsymbol {\omega }}&=\nabla \times \mathbf {u} \\\left(\mathbf {u} \cdot \nabla \right)\mathbf {u} &=\nabla \left({\frac {1}{2}}\mathbf {u} \cdot \mathbf {u} \right)-\mathbf {u} \times {\boldsymbol {\omega }}\\\nabla \times \left(\mathbf {u} \times {\boldsymbol {\omega }}\right)&=-{\boldsymbol {\omega }}\left(\nabla \cdot \mathbf {u} \right)+\left({\boldsymbol {\omega }}\cdot \nabla \right)\mathbf {u} -\left(\mathbf {u} \cdot \nabla \right){\boldsymbol {\omega }}\\[4pt]\nabla \cdot {\boldsymbol {\omega }}&=0\\[4pt]\nabla \times \nabla \phi &=0\end{aligned}}}
No. 237 Squadron, based in Kenya since before the start of the war, had expanded to 28 officers and 209 other ranks by March 1940. By mid-1940, most of the officers and men Southern Rhodesia had sent overseas were in Kenya, attached to various East African formations, the King's African Rifles (KAR), the RWAFF, or to the colony's own Medical Corps or Survey Unit. The Southern Rhodesian surveyors charted the previously unmapped area bordering Abyssinia and Italian Somaliland between March and June 1940, and the Medical Corps operated No. 2 General Hospital in Nairobi from July. A company of coloured and Indian-Rhodesian transport drivers was also in the country, having arrived in January. The first Southern Rhodesian contingent despatched to North Africa and the Middle East was a draft of 700 from the Rhodesia Regiment who left in April 1940. No white Rhodesian force of this size had ever left the territory before. They were posted to a variety of British units across Egypt and Palestine. The largest concentration of Rhodesian soldiers in North Africa belonged to the King's Royal Rifle Corps (KRRC), whose connections with the colony dated back to World War I. Several Rhodesian platoons were formed in the KRRC's 1st Battalion in the Western Desert. A company of men from the Southern Rhodesian Signal Corps was also present, operating in tandem with the British Royal Corps of Signals.
Clinical studies have repeatedly shown that even though insulin resistance is usually associated with obesity, the membrane phospholipids of the adipocytes of obese patients generally still show an increased degree of fatty acid unsaturation. This seems to point to an adaptive mechanism that allows the adipocyte to maintain its functionality, despite the increased storage demands associated with obesity and insulin resistance. A study conducted in 2013 found that, while INSIG1 and SREBF1 mRNA expression was decreased in the adipose tissue of obese mice and humans, the amount of active SREBF1 was increased in comparison with normal mice and non-obese patients. This downregulation of INSIG1 expression combined with the increase of mature SREBF1 was also correlated with the maintenance of SREBF1-target gene expression. Hence, it appears that, by downregulating INSIG1, there is a resetting of the INSIG1/SREBF1 loop, allowing for the maintenance of active SREBF1 levels. This seems to help compensate for the anti-lipogenic effects of insulin resistance and thus preserve adipocyte fat storage abilities and availability of appropriate levels of fatty acid unsaturation in face of the nutritional pressures of obesity.
Sources: en.wikipedia.org
=== Campaign history === 2012 US Senate election: 2,249 votes (0.07%) 2009 Gubernatorial election: 2,085 votes (0.09%) 2006 US Senate election: 2,490 votes (0.1%) 2002 US Senate election: 2,702 votes (0.13%) 2000 US Senate election: 3,365 votes (0.11%) 1997 Gubernatorial election: 2,800 votes (0.12%) 1994, District 9 Congressional election: 1,490 votes (0.93%)
=== Zwitterion === Zwitterions contain an anionic and a cationic centre in the same molecule, but are not considered salts. Examples of zwitterions are amino acids, many metabolites, peptides, and proteins.
Peptide T is an HIV entry inhibitor discovered in 1986 by Candace Pert and Michael Ruff, a US neuroscientist and immunologist. Peptide T, and its modified analog Dala1-peptide T-amide (DAPTA), a drug in clinical trials, is a short peptide derived from the HIV envelope protein gp120 which blocks binding and infection of viral strains which use the CCR5 receptor to infect cells. DAPTA was initially administered as a nasal spray, but this formulation was found to be unstable. A more stable oral form, called RAP-103, is a shorter pentapeptide derived from DAPTA. RAP-103 is a CCR2/CCR5 antagonist that protects synapses by blocking the synaptotoxic actions of oligomeric forms of amyloid beta and alpha-synuclein., as well as HIV gp120, via a PrPc dependent pathway. Synapse loss underlies the cognitive losses attributed to these toxic proteins and the ensuing clinical conditions of AD, LBD, and HAND, which these peptide chemokine receptor antagonists may safely treat. In preclinical studies, RAP-103 has also been shown to prevent and reverse neuropathic pain and to reduce opioid addiction liability. Peptide T has several positive effects related to HIV disease and Neuro-AIDS. A FDG-PET neuro-imaging study in an individual with AIDS dementia who completed a 12-wk treatment with intranasal DAPTA, showed remission in 34 out of 35 brain regions after treatment. A placebo-controlled, three site, 200+ patient NIH-funded clinical trial, which focused on neurocognitive improvements, was conducted between 1990 and 1995.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.